CompletedHealthcare30 October 2026

Azenta, Inc. to acquire SynPlexity Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Azenta, Inc.
Target
SynPlexity Inc.
Deal value
Not disclosed
Announced
30 October 2026
Status
Completed
Sector
Healthcare
Country
United States
Consideration
Not stated
What we know

Azenta, Inc. acquired SynPlexity Inc. on October 28, 2026, by entering into a Stock Purchase Agreement with SynPlexity, its stockholders and other parties. Under the agreement, Azenta acquired all of SynPlexity's issued and outstanding capital stock. The acquisition closed concurrently with execution of the agreement, so signing and completion fell on the same day. Azenta disclosed the deal in a Form 8-K and said it issued a press release announcing the acquisition on October 30, 2026.

The filing describes SynPlexity as a DNA assembly technology company. Its products and services center on large, multiplexed gene libraries for functional screening, drug discovery, therapeutics and other applications. Azenta said the acquisition adds technology and expertise that it intends to integrate into its GENEWIZ synthesis portfolio.

The 8-K does not state a purchase price or the form of consideration for SynPlexity. Its forward-looking statements, which cover both the acquisition and the Elegen arrangements, mention potential contingent payments without attributing them to either transaction or giving an amount or terms.

Azenta reported the SynPlexity purchase alongside, but separately from, two agreements signed the same day with Elegen Corp.: a Technology, Equipment and License Agreement and a Master Services and Supply Agreement. The filing states that the acquisition and the Elegen arrangements are separate transactions, each intended to support the continued development of Azenta's DNA synthesis capabilities. The Elegen license has an initial term of five years, and the capital deployment figures in the filing (expected to range from approximately $32 million to approximately $71 million) relate to the Elegen agreements, not to the SynPlexity purchase.

Deal timeline

1 update
  1. CompletedClosed

    Azenta, Inc. completes acquisition of SynPlexity Inc.

    Item 1.01. Entry into a Material Definitive Agreement . On October 28, 2026, Azenta, Inc. (“Azenta” or the “Company”) entered into a Technology, Equipment and License Agreement (the “License Agreement”) and a Master Services and Supply Agreement (the “Supply Agreement” and, together with the License Agreement, the “Elegen Agreements”) with Elegen Corp. (“Elegen”). The Elegen Agreements form an int

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

Azenta, Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive